Post-Catalyst Behavior Patterns
How biotech stocks typically behave after FDA catalysts. Not predictions. Not signals. Behavioral tendencies drawn from historical data and observed patterns.
Understanding Post-Catalyst Behavior
When the FDA makes a decision, the stock doesn't just go up or down. The behavior unfolds in phases — an initial reaction, a secondary adjustment, and a longer-term trajectory. Understanding these phases helps you plan entries, exits, and position sizes before the event happens.
The scanner assigns each upcoming PDUFA event a set of behavioral probability estimates based on the setup's characteristics. These are not prediction scores — they describe how stocks with similar setups have historically behaved.
The Five Behavioral Patterns
A sharp initial move upward in the hours following FDA approval. This is the most common retail expectation — the "pop" on good news. The spike typically occurs in after-hours or premarket trading and may fade once the regular session opens.
→ Low PoA (surprise approval) · Low STN Risk · Depressed stock price
→ High short interest (squeeze) · First-ever approval for company
→ Large market indication · No active ATM/shelf
A significant decline in the days following a catalyst — even on positive news. This is the sell-the-news phenomenon at its most severe. The stock may spike briefly, then reverse hard as institutions sell into retail buying, dilution is announced, or the market re-prices commercial reality.
→ HIGH STN Risk · Unanimous AdCom (priced in) · Resubmission after CRL
→ Active ATM/shelf registration · Runway <12 months · Insider selling
→ Ultra-rare indication (limited revenue) · sNDA/supplement (incremental)
Not just a spike, but sustained upward movement over days to weeks following approval. This happens when the market gradually prices in the full commercial value of the drug, institutional buyers accumulate, and no dilution occurs to cap the rally.
→ First-in-class drug · Large addressable market · No competition
→ Partnership/co-commercialization in place · Strong runway (>24 months)
→ Insider buying cluster · No shelf/ATM · Low institutional ownership (room to accumulate)
Some approvals make the company an acquisition target. Large pharma companies regularly acquire smaller biotechs after FDA approval to add the drug to their portfolio without the development risk. This pattern typically takes weeks to months to develop but can result in premium buyout offers well above the post-approval price.
→ First-in-class with large market · Small-cap with single approved product
→ Drug fills gap in large pharma portfolio · Clean label (no REMS/black box)
→ Company has no commercial infrastructure (easier to acquire than to compete)
→ PRV eligible (additional value) · Therapeutic area with active M&A history
Sometimes the market barely reacts to an approval. The stock moves 0-5% and then drifts. This doesn't mean the approval is bad — it means the market already fully priced it in, or the commercial opportunity isn't exciting enough to drive new buying.
→ Very high PoA (>85%) and everyone expected it · sNDA for known drug
→ Large-cap company where one drug doesn't move the needle
→ Competitive market with existing treatments · Stock already at fair value
→ ELEVATED STN Risk with no squeeze catalyst
How the Scanner Uses These Patterns
Each PDUFA event in the scanner is assessed against all five patterns simultaneously. The combination of PoA, STN Risk, Dilution Radar, runway, insider activity, and market cap tier determines which behavioral pattern is most likely.
A single event can have elevated probability for multiple patterns. For example, RCKT had moderate probability of both a post-approval spike (which happened briefly in premarket) AND a deep dive (which dominated by market open). The scanner flagged HIGH STN Risk, which correctly predicted the deep dive would overpower the spike.
The goal isn't to predict the exact move. The goal is to understand which behaviors are most likely so you can plan your trade accordingly — when to take profits, when to hold, when to avoid, and how to size your position relative to the risk.
Full Biotech Universe Coverage
Submarine Catalyst now tracks PDUFA events across the entire biotech universe — small-cap, mid-cap, and large-cap companies. This matters because behavioral patterns differ significantly by market cap tier:
Small-cap ($0-$2B): Highest volatility. Most susceptible to deep dives from dilution. But also the highest spike and buyout wave potential. This is where the asymmetric trades live.
Mid-cap ($2B-$10B): More institutional coverage means more efficient pricing. Spikes are moderate (+10-25%). Deep dives are less common but still occur on sNDA/label expansion events. Buyout potential is real but at higher premiums.
Large-cap ($10B+): Surface-level reactions are the norm. One drug approval rarely moves the needle. These are tracked for completeness and for understanding competitive dynamics that affect smaller companies in the same therapeutic area.
How to Use This
Before every PDUFA trade, check which behavioral pattern the scanner flags as most likely. Then build your plan around that pattern — not around hope.
If the scanner says HIGH STN Risk and the deep dive pattern is elevated, plan to sell into the premarket spike or avoid the trade entirely. If the scanner says LOW STN Risk and the spike pattern is elevated, size accordingly and set your profit target before the event.
The traders who consistently make money on PDUFA events are the ones who plan for specific behaviors instead of just betting on direction. This page — and the scanner — exists to make that planning systematic.
New to PDUFA trading? Start with the Beginner's Guide →
Get Access — $29.99/monthFull scanner · All risk layers · AI research · Behavioral patterns